Registro:

Referencias:

• Günther, S., Lenz, O., Lassa virus (2004) Crit Rev Clin Lab Sci, 41, pp. 339-390
• Enría, D.A., Briggiler, A.M., Sánchez, Z., Treatment of Argentine hemorrhagic fever (2008) Antiviral Res, 78, pp. 132-139
• McCormick, J.B., King, I.J., Webb, P.A., Lassa fever. Effective therapy with ribavirin (1986) N Engl J Med, 314, pp. 20-26
• Linero, F.N., Sepúlveda, C.S., Giovannoni, F., Host cell factors as antiviral targets in arenavirus infection (2012) Viruses, 4, pp. 1569-1591
• Debing, Y., Neyts, J., Delang, L., The future of antivirals: broad-spectrum inhibitors (2015) Curr Opin Infect Dis, 28, pp. 596-602
• Pasquato, A., Kunz, S., Novel drug discovery approaches for treating arenavirus infections (2016) Expert Opin Drug Discov, 11, pp. 383-393
• Streeter, D.G., Witkowski, J.T., Khare, G.P., Mechanism of action of 1-ß-D-ribofuranosyl-1, 2, 4-triazole-3- carboxamide (Virazole), a new broad-spectrum antiviral agent (1973) Proc Natl Acad Sci USA, 70, pp. 1174-1178
• Andrei, G., De Clercq, E., Molecular approaches for the treatment of hemorrhagic fever virus infections (1993) Antiviral Res, 22, pp. 45-75
• Guillerm, G., Guillerm, D., Vandenplas-Vitkowski, C., Glapski, C., De Clercq, E., Inactivation of S-adenosyl-L-homocysteine hydrolase with novel 5'-thioadenosine derivatives. Antiviral effects (2003) Bioorg Med Chem Lett, 13, pp. 649-1652
• Gowen, B.B., Wong, M.H., Larson, D., Development of a new Tacaribe arenavirus infection model and its use to explore antiviral activity of a novel aristeromycin analog (2010) PLoS ONE, 16
• Ölschläger, S., Neyts, J., Günther, S., Depletion of GTP pool is not the predominant mechanism by which ribavirin exerts its antiviral effect on Lassa virus (2011) Antiviral Res, 91, pp. 89-93
• Sepúlveda, C.S., García, C.C., Fascio, M.L., Inhibition of Junín virus RNA synthesis by an antiviral acridone derivative (2012) Antiviral Res, 93, pp. 16-22
• Ortiz-Riaño, E., Ngo, N., Devito, S., Inhibition of arenavirus by A3, a pyrimidine biosynthesis inhibitor (2014) J Virol, 88, pp. 878-889
• Sanders, S., Harisdangkul, V., Leflunomide for the treatment of rheumatoid arthritis and autoimmunity (2002) Am J Med Sci, 323, pp. 190-193
• Oh, J., O'Connor, P.W., An update of teriflunomide for treatment of multiple sclerosis (2013) Ther Clin Risk Manag, 9, pp. 177-190
• Davis, J.P., Cain, G.A., Pitts, W.J., Magolda, R.L., Copeland, R.A., The immunosuppressive metabolite of leflunomide is a potent inhibitor of human dihydroorotate dehydrogenase (1996) Biochemistry, 35, pp. 1270-1273
• Mattar, T., Kochhar, K., Bartlett, R., Bremer, E.G., Finnegan, A., Inhibition of the epidermal growth factor receptor tyrosine kinase activity by leflunomide (1993) FEBS Lett, 334, pp. 161-164
• Elder, R.T., Xu, X., Williams, J.W., Gong, H., Finnegan, A., Chong, A.S.-F., The immunosuppressive metabolite of leflunomide, A77 1726, affects murine T cells through two biochemical mechanisms (1977) J Immunol, 159, pp. 22-27
• Hamilton, L.C., Vojnovic, I., Warner, T.D., A771726, the active metabolite of leflunomide, directly inhibits the activity of cyclo-oxygenase-2 in vitro and in vivo in a substrate-sensitive manner (1999) Br J Pharmacol, 127, pp. 1589-1596
• Manna, S.K., Aggarwal, B.B., Immunosuppressive leflunomide metabolite (A77 1726) blocks TNF-dependent nuclear factor-kappa B activation and gene expression (1999) J Immunol, 162, pp. 2095-2102
• Knight, D.A., Hejmanowski, A.Q., Dierksheide, J.E., Williams, J.W., Chong, A.S.-F., Waldman, J., Inhibition of herpes simplex virus type 1 by the experimental immunosuppressive agent leflunomide (2001) Transplantation, 71, pp. 170-174
• Waldman, W.J., Knight, D.A., Lurain, N.S., Novel mechanism of inhibition of cytomegalovirus by the experimental immunosuppressive agent leflunomide (1999) Transplantation, 68, pp. 814-825
• Evers, D.L., Wang, X., Huong, S.M., Andreoni, K.A., Huang, E.S., Inhibition of human cytomegalovirus signaling and replication by the immunosuppressant FK778 (2005) Antiviral Res, 65, pp. 1-12
• Bernhoff, E., Tylden, G.D., Kjerpeseth, L.J., Gutteberg, T.J., Hirsch, H.H., Rinaldo, C.H., Leflunomide inhibition of BK virus replication in renal tubular epithelial cells (2010) J Virol, 84, pp. 2150-2156
• Jeffers-Francis, L.K., Burger-Calderón, R., Webster-Cyriaque, J., Effect of leflunomide, cidofovir and ciprofloxacin on replication of BKPyV in a salivary gland in vitro culture system (2015) Antiviral Res, 118, pp. 46-55
• Schläpfer, E., Fischer, M., Ott, P., Speck, R.F., Anti-HIV-1 activity of leflunomide: a comparison with mycophenolic acid and hydroxyurea (2003) AIDS, 17, pp. 1613-1620
• Dunn, M.C., Knight, D.A., Waldman, W.J., Inhibition of respiratory syncytial virus in vitro and in vivo by the immunosuppressive agent leflunomide (2011) Antiviral Ther, 16, pp. 309-317
• Avery, R.K., Mossad, S.B., Poggio, E., Utility of leflunomide in the treatment of complex cytomegalovirus syndromes (2010) Transplantation, 90, pp. 419-426
• Henao-Martínez, A.F., Weinberg, A., Waldman, W.J., Levi, M.E., Successful treatment of acyclovir-resistant herpes simplex virus type 2 proctitis with leflunomide in an HIV-infected man (2012) J Clin Virol, 54, pp. 276-278
• El Chaer, F., Mori, N., Shah, D., Adjuvant and salvage therapy with leflunomide for recalcitrant cytomegalovirus infections in hematopoietic cell transplantation recipients: a case series (2016) Antiviral Res, 135, pp. 91-96
• Morita, S., Shinoda, K., Tamaki, S., Successful low-dose leflunomide treatment for ganciclovir-resistant cytomegalovirus infection with high-level antigenemia in a kidney transplant: a case report and literature review (2016) J Clin Virol, 82, pp. 133-138
• Chen, X.C., Liu, T., Li, J.J., He, C., Meng, W.T., Huang, R., Efficacy and safety of leflunomide for the treatment of BK virus-associated hemorrhagic cystitis in allogeneic hematopoietic stem cell transplantation recipients (2013) Acta Haematol, 130, pp. 52-56
• Jung, Y.H., Moon, K.C., Ha, J.W., Leflunomide therapy for BK virus allograft nephropathy after pediatric kidney transplantation (2013) Pediatr Transplant, 17, pp. E50-E54
• Contigiani, M.S., Sabattini, M.S., Virulencia diferencial de cepas de virus Junin por marcadores biológicos en ratones y cobayos (1977) Medicina (Bs Aires), 37, pp. 244-251
• de Guerrero, L.B., Weissenbacher, M.C., Parodi, A.S., Inmunización contra la fiebre hemorrágica argentina con una cepa atenuada de virus Junin. Inmunización de cobayos (1969) Medicina (Bs Aires), 29, pp. 1-5
• Maiztegui, J.I., McKee, K.T., Barrera Oro, J.G., Protective efficacy of a live attenuated vaccine against Argentine hemorrhagic fever (1998) J Infect Dis, 177, pp. 277-283
• Talarico, L.B., Damonte, E.B., Interference in dengue virus adsorption and uncoating by carrageenans (2007) Virology, 363, pp. 473-485
• Ellenberg, P., Linero, M.F., Scolaro, L.A., Superinfection exclusion in BHK-21 cells persistently infected with Junín virus (2007) J Gen Virol, 88, pp. 2730-2739
• Moreno, H., Gallego, I., Sevilla, N., de la Torre, J.C., Domingo, E., Martín, V., Ribavirin can be mutagenic for arenaviruses (2011) J Virol, 85, pp. 7246-7255
• Evans, D.R., Guy, H.I., Mammalian pyrimidine biosynthesis: fresh insights into an ancient pathway (2004) J Biol Chem, 279, pp. 33035-33038
• Qing, M., Zou, G., Wang, Q.-Y., Characterization of dengue virus resistance to brequinar in cell culture (2010) Antimicrob Agents Chemother, 54, pp. 3686-3695
• Vela, E.M., Knostman, K.A., Mott, J.M., Genistein, a general kinase inhibitor, as a potential antiviral for arenaviral hemorrhagic fever as described in the Pirital virus-Syrian golden hamster model (2010) Antiviral Res, 87, pp. 318-328
• Kolokoltsov, A.A., Adhikary, S., Garver, J., Johnson, L., Davey, R.A., Vela, E.M., Inhibition of Lassa and Ebola virus infection in host cells treated with the kinase inhibitors genistein and tyrphostin (2012) Arch Virol, 157, pp. 121-127
• Chung, D.H., Golden, J.E., Adcock, R.S., Discovery of a broad-spectrum antiviral compound that inhibits pyrimidine biosynthesis and establishes a type 1 interferon-independent antiviral state (2016) Antimicrob Agents Chemother, 60, pp. 4552-4562
• Lucas-Hourani, M., Dauzonne, D., Jorda, P., Inhibition of pyrimidine biosynthesis pathway suppresses viral growth through innate immunity (2013) PLoS Pathog, 9
• Wang, Y., Wang, W., Xu, L., Cross talk between nucleotide synthesis pathways with cellular immunity in constraining hepatitis E virus replication (2016) Antimicrob Agents Chemother, 60, pp. 2834-2848
• Diaz, M.O., Ziemin, S., Le Beau, M.M., Homozygous deletion of the alpha- and beta 1-interferon genes in human leukemia and derived cell lines (1988) Proc Natl Acad Sci USA, 85, pp. 259-5263
• Marschall, M., Niemann, I., Kosulin, K., Assessment of drug candidates for broad-spectrum antiviral therapy targeting cellular pyrimidine biosynthesis (2013) Antiviral Res, 100, pp. 640-648

Citas:

---------- APA ----------

---------- CHICAGO ----------

---------- MLA ----------

---------- VANCOUVER ----------